Draft of USP Chapter <711> Dissolution (PDG harmonized document) Published for Comments
Recommendation

Tuesday, 10 February 2026 13.00 - 17.30 h
In the Pharmacopeial Forum, PF 49(3), a proposal of a revised USP General Chapter <711> Dissolution has been published for comments. The background to the publication is the efforts of international harmonization of monographs and general analytical methods of the European, Japanese, and United States pharmacopeias.
The Pharmacopoeial Discussion Group (PDG)
The Pharmacopoeial Discussion Group (PDG), which was created in 1989, brings together
- the Japanese Pharmacopoeia (JP),
- the European Pharmacopoeia (Ph. Eur.),
- and the United States Pharmacopeia (USP).
The PDG works on pharmacopoeial harmonization of excipient monographs and general chapters.
Revised USP Chapter <711> Dissolution
The now published proposal is based on the version of the USP chapter official since 01 May 2023. It represents the official inquiry stage 2A of Revision 5 to the PDG harmonized document.
According to the briefing notes, the draft includes changes in the following sections:
- "Apparatus, Apparatus 1 (basket apparatus)
- Apparatus 3 (Reciprocating Cylinder)
- Apparatus 4 (Flow-Through Cell)
- Apparatus 4 (Flow-Through Cell), Apparatus Suitability
- Procedure, Apparatus 1 and Apparatus 2, Immediate-Release Dosage Forms
- Procedure, Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms
- Procedure, Apparatus 3 (reciprocating cylinder), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Procedure, Apparatus 4 (Flow-through Cell), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Interpretation, Immediate-Release Dosage Forms, Acceptance Table 1
- Interpretation, Extended-Release Dosage Forms, Acceptance Table 2
- Interpretation, Delayed-Release Dosage Forms, Acid Stage, Acceptance Table 3, and Buffer Stage, Acceptance Table 4"
The draft of the revised chapter is available on PF Online. The comment period is open from now on until 31 July 2023.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods


